[Profile & Vision] Founded in January 2018 as an Osaka University deep-tech startup, Immunosens is based at the National Cerebral and Cardiovascular Center. Our vision is to realize medical-grade health checks "anytime, anywhere, and for anyone" by integrating high-performance testing into daily life to extend healthy life expectancy. Total funding: ¥1.22B.
[Core Technology: GLEIA®] Our proprietary GLEIA® (Gold-Linked Electrochemical Immunoassay) technology electrochemically quantifies gold nanoparticle antibody labels. It enables high-precision, ultra-compact testing previously only possible with large-scale laboratory analyzers.
Ultra-High Sensitivity: Detects concentrations as low as 1 pg/mL (one-trillionth of a gram).
Rapid Results: Delivers quantitative data in approximately 10 minutes.
Minimal Sample: Requires just one drop (2–20 μL) of blood, saliva, or urine.
[Product Portfolio] We provide single-use disposable sensors and two dedicated readers:
Medical Reader (180g): A palm-sized device for immediate diagnosis in clinics and during home-visit care.
Self-Check Reader (44g): An ultra-compact device that connects to smartphones via Bluetooth for daily home monitoring.
Key Applications: Certified items include D-dimer (thrombosis) and NT-proBNP (heart failure management), alongside sIgA for athlete conditioning.
[3-Step Social Implementation Strategy]
STEP 1: Healthcare & Animal Health: Partnering with key players like Kirin to visualize immune-care effects (sIgA) and expanding into the animal POCT market.
STEP 2: Rapid Diagnosis (POCT): Promoting in-hospital testing to support immediate clinical decisions by physicians.
STEP 3: Disease Management & Telemedicine: Establishing a "Diabetes Management Model for Heart Failure," allowing patients to measure markers at home and share data instantly with physicians to prevent re-hospitalization.